Skip to main content
Fig. 2 | Cancer Nanotechnology

Fig. 2

From: Targeting nano-regulator based on metal–organic frameworks for enhanced immunotherapy of bone metastatic prostate cancer

Fig. 2

A The cell viability of the RM-1 cells after treatment with free MTO and MTO@PA/Fe3+ MOF. B CRT exposure, C HMGB1 expression, and D ATP release for the RM-1 cells treatment with free MTO and MTO@PA/Fe3+ MOF. E TGF-β/TβR recognition to induce SMAD phosphorylation for signal transduction, and the mechanism of MTO to block TGF-β function. The cell viability of F DCs and G T cells after treatment with free MTO and MTO@PA/Fe3+ MOF. The expression of SMAD and p-SMAD upon various treatments, and the quantified results for H, J DCs and I, K T cells

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us